Molecular Imaging of Pancreatic Cancer with Antibodies

England, Christopher G.; Hernandez, Reinier; Eddine, Savo Bou Zein; Cai, Weibo

doi:10.1021/acs.molpharmaceut.5b00626

Cited by 63 publications

(62 citation statements)

References 210 publications

(430 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The added value of PET for staging and diagnosis of pancreatic cancer is controversial [40]. In addition to conventional imaging techniques, biomarker-based imaging using molecular probes, nanoparticles or antibodies, are being evaluated in experimental settings and may ultimately aid in early cancer detection and development of novel therapeutic strategies [41,42]. …”

mentioning

confidence: 99%

Pancreatic Cancer: Yesterday, Today and Tomorrow

et al. 2016

View full text Add to dashboard Cite

Pancreatic cancer is one of our most lethal malignancies. Despite substantial improvements in the survival rates for other major cancer forms, pancreatic cancer survival rates have remained relatively unchanged since the 1960s. Pancreatic cancer is usually detected at an advanced stage and most treatment regimens are ineffective, contributing to the poor overall prognosis. Herein, we review the current understanding of pancreatic cancer, focusing on central aspects of disease management from radiology, surgery and pathology to oncology. Historical remarks & present stateThe first known description of pancreatic cancer is attributed to Giovanni Battista Morgagni in his 1761 publication 'de Sedibus Et Causis Morborum Per Anatomen Indagatis Libri Quinque' [1]. However, the lack of a microscopic evaluation makes the true diagnosis of ductal adenocarcinoma uncertain. The next important advancement in our understanding of pancreatic cancer did not come until 1858, when Jacob Mendez Da Costa revisited Morgagni's original work and also described the first microscopic diagnosis of adenocarcinoma, manifesting pancreatic cancer as a true disease entity [2].The history of pancreatic surgery is fairly recent and involves a combination of brave surgical pioneers, the development of surgical anesthesia and modern aseptic techniques. Some landmarks in the history of pancreatic surgery deserve to be mentioned. The first reported attempt at a pancreaticoduodenectomy was performed in 1898 by the Italian surgeon Alessandro Codivilla for a tumor involving the head of the pancreas [3]; however, the patient did not survive the postoperative period. In the same year, William Stewart Halsted from Johns Hopkins Hospital performed the first successful resection for ampullary cancer by excising portions of the duodenum and the pancreas [4]. The first successful pancreaticoduodenectomy is credited to the German surgeon Walther Carl Eduard Kausch, as part of a two-stage procedure [5]. In 1914, Georg Hirschel performed the first successful pancreaticoduodenectomy in one stage [6] and then in 1935, Allen Oldfather Whipple presented the results of a two-stage procedure involving the resection of the head of the pancreas and duodenum for ampullary carcinoma at the annual meeting of the American Surgical Association, which renewed interest in pancreatic surgery [7]. During his career, Whipple performed 37 pancreaticoduodenectomies, with the procedure evolving into a one-stage technique [8,9], and 1964-1968 1969-1973 1974-1978 1979-1983 1984-1988 1989-1993 1994-1998 1999-2003 2004-2008 2009-2013 Period of diagnosis Whipple is generally credited with popularizing the operation that still bears his name. In 1937, Alexander Brunschwig performed the first successful pancreaticoduodenectomy for pancreatic adenocarcinoma [10]. Today, with the concentration of experience in high-volume hospitals, pancreatic surgery has become a safe procedure associated with an operative mortality below 3% [11][12][13]. While major advances have been made ...

show abstract

mentioning

confidence: 99%

Pancreatic Cancer: Yesterday, Today and Tomorrow

et al. 2016

View full text Add to dashboard Cite

show abstract

“…For photoacoustic imaging to visualize biomarkers of PDAC, molecular probes must be developed and evaluated for extravasation, binding efficiency, excretion, and toxicity. 79 Early stage preclinical applications in pancreatic cancer animal models support the value of photoacoustic imaging for early detection of PDAC, 80 pending further development of operational and visualization techniques.…”

Section: Eus and New Technologiesmentioning

confidence: 99%

Endoscopic Ultrasound and Related Technologies for the Diagnosis and Treatment of Pancreatic Disease - Research Gaps and Opportunities

et al. 2017

View full text Add to dashboard Cite

A workshop was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases to address the research gaps and opportunities in pancreatic endoscopic ultrasound (EUS). The event occurred on July 26, 2017 in 4 sessions: (1) benign pancreatic diseases, (2) high-risk pancreatic diseases, (3) diagnostic and therapeutics, and (4) new technologies. The current state of knowledge was reviewed, with identification of numerous gaps in knowledge and research needs. Common themes included the need for large multicenter consortia of various pancreatic diseases to facilitate meaningful research of these entities; to standardize EUS features of different pancreatic disorders, the technique of sampling pancreatic lesions, and the performance of various therapeutic EUS procedures; and to identify high-risk disease early at the cellular level before macroscopic disease develops. The need for specialized tools and accessories to enable the safe and effective performance of therapeutic EUS procedures also was discussed.

show abstract

“…In addition, they both have relatively low spatial resolution in localizing the tumors. The relatively slow data acquisition time of MRI often generates motion artifact issue and a reduced signal-to-noise ratio [21]. In optical imaging, fluorescent dyes, quantum dots, or nanoparticles conjugated to targeted antibodies or peptides are commonly used as contrast agents.…”

Section: Introductionmentioning

confidence: 99%

Targeted Molecular Imaging of Pancreatic Cancer with a Miniature Endoscope

et al. 2017

View full text Add to dashboard Cite

It is highly desirable to develop novel approaches to improve patient survival rate of pancreatic cancer through early detection. Here, we present such an approach based on photoacoustic and fluorescence molecular imaging of pancreatic tumor using a miniature multimodal endoscope in combination with targeted multifunctional iron oxide nanoparticles (IONPs). A novel fan-shaped scanning mechanism was developed to minimize the invasiveness for endoscopic imaging of pancreatic tumors. The results show that the enhancements in photoacoustic and fluorescence signals using amino-terminal fragment (ATF) targeted IONPs were~four to six times higher compared to that using non-targeted IONPs. Our study indicates the potential of the combination of the multimodal photoacoustic-fluorescence endoscopy and targeted multifunctional nanoparticles as an efficient tool to provide improved specificity and sensitivity for pancreatic cancer detection.

show abstract

Molecular Imaging of Pancreatic Cancer with Antibodies

Cited by 63 publications

References 210 publications

Pancreatic Cancer: Yesterday, Today and Tomorrow

Pancreatic Cancer: Yesterday, Today and Tomorrow

Endoscopic Ultrasound and Related Technologies for the Diagnosis and Treatment of Pancreatic Disease - Research Gaps and Opportunities

Targeted Molecular Imaging of Pancreatic Cancer with a Miniature Endoscope

Contact Info

Product

Resources

About